There are 2137 resources available
1971P - Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients
Presenter: Natalia Jimenez
Session: E-Poster Display
Resources:
Abstract
1972P - Circular RNA is associated with enzalutamide resistant prostate cancer
Presenter: Marvin Lim
Session: E-Poster Display
Resources:
Abstract
1973P - Membranous vimentin (Vim) expression as a possible surrogate of cell surface vimentin in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: E-Poster Display
Resources:
Abstract
1974P - MediGrid: A novel interface for real time collection and analysis of real world clinical data
Presenter: Anna Olsson-Brown
Session: E-Poster Display
Resources:
Abstract
1975P - Artificial Intelligence-based tool to generate directional integrative treatment reports for cancer patients (ZIOPAR: ZenOnco.io Integrative Oncology Preliminary Assessment Report)
Presenter: Kishan Shah
Session: E-Poster Display
Resources:
Abstract
1976TiP - A multi-national study of treatment resistance following anti-cancer therapy (TRANSLATE)
Presenter: Carole Helissey
Session: E-Poster Display
Resources:
Abstract
1981P - RelB silencing reversed tamoxifen resistance by regulating GPx4 and ferroptosis in breast cancer
Presenter: Zhi Xu
Session: E-Poster Display
Resources:
Abstract
1983P - Metronomic combination of 5-fluorouracil plus vinorelbine limits endothelial and triple-negative breast cancer cells proliferation and migration and abolishes clonogenic survival
Presenter: Maria Grazia Cerrito
Session: E-Poster Display
Resources:
Abstract
1982P - Fibroblasts-derived matrices confer resistance to oxaliplatin and cetuximab in a snail-dependent way in CRC
Presenter: Cristina Galindo Pumariño
Session: E-Poster Display
Resources:
Abstract
1984P - Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to progression in patients undergoing neo-adjuvant chemotherapy
Presenter: Bernardo Rapoport
Session: E-Poster Display
Resources:
Abstract